An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma

An oncolytic herpes simplex virus armed with IL-12 for treatment of preclinical glioblastoma

Glioblastoma (GBM) is a devastating brain cancer with a 5-year survival rate of ∼5% despite current treatment regimens. Multiple oncolytic herpes simplex viruses (oHSV) have been designed for GBM therapy, but clinical trials have thus far met with limited success. A potential reason for this lack of...

Full description

Saved in:
Bibliographic Details
Main Authors: Joseph W. Jackson, Bonnie L. Hall, Chaim Sneiderman, Amy Webb, Trevor J. Hancock, Marina Vlasyuk, Lisa Bailey, Molly Xiaokui, Isaac H. Solomon, Keith Ligon, William F. Goins, Gary Kohanbash, E. Antonio Chiocca, Joseph C. Glorioso
Format: Article
Language:English
Published: Elsevier 2025-09-01
Series:Molecular Therapy: Oncology
Subjects:
HSV
oncolytic
GBM
cancer
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2950329925000992
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2950329925000992

Similar Items